Bringing Nuvaxovid™ to Market: A Novavax Case Study

Introduction In the dynamic world of biotechnology, the intersection of passion and knowledge often paves the path for revolutionary breakthroughs. Since 2014, Biointelect have supported Novavax – a global company advancing protein-based vaccines with its Matrix-M™ adjuvant based in Gaithersburg, Md., U.S. –  since 2014 (phase 1) with Australian and New Zealand medical affairs, policy, […]

HTA Roadmap For a New Vaccine in Australia

The landscape of vaccines in Australia is marked by stringent guidelines and a competitive marketplace and above all a focus on patient outcomes. 

Biointelect partnered with a pharmaceutical company, well-versed in the Australian market but new to the vaccine domain, to develop a roadmap that would not only introduce their new vaccine but also potentially secure it a coveted position on the National Immunisation Program (NIP) with premium pricing.

Navigating European Market Access: A Strategic Blueprint for Novel Vaccines

Introduction The European medical market is the second-largest medical device market following the US, requiring newfound innovation for pharmaceutical companies to reach success. A US Biotech firm, on the cusp of introducing a groundbreaking first-in-class vaccine, sought Biointelect’s expertise to illuminate their path in this intricate and highly saturated market.  With Biointelect’s strategic guidance and […]